Printer Friendly

IMPRESSION DELIVERY CORPORATION ACQUIRES AIDS-TREATMENT TECHNOLOGY

 MINNEAPOLIS, Feb. 22 /PRNewswire/ -- Impression Delivery Corporation announced today that it has acquired, under an exclusive, perpetual license, proprietary drug technology related to the treatment of AIDS and certain other viral infections as developed by BioLogic Incorporated of Minneapolis. The license agreement provides a royalty and long-term employment agreement for Ric Rotondo, CEO of BioLogic and the scientist who is responsible for developing the drug technology.
 The drug for AIDS treatment is one of a family of new drugs in development by Rotondo over the course of nearly 11 years. The results of over 2,000 in vitro tests have confirmed a 100 percent viral reduction of HIV viruses that cause AIDS. Studies are currently under way to confirm the exact details of synthesis, the process that will be used in manufacturing the drug. Within two weeks, results are expected from those tests.
 The company has established a high priority for animal studies. Those studies, it believes, will demonstrate that the drug, while highly effective, will not result in the extraordinary toxicity that is so commonly associated with AIDS drug treatment protocol. The results of such toxicity are well documented in connection with kidney failure and severe side effects in humans. The subsequent step will involve clinical studies in humans. The company has had a significant number research facilities express interest in participating in such studies.
 "We believe this technology, specifically the AIDS treatment drug, can become available soon," stated John Priscella, CEO of Impression Delivery Corporation. He added, "This technology has tremendous human value, as well as intellectual property value. For the benefit of a great number of people, we are hopeful that the new administration and regulatory authorities will provide an extra measure of support and due diligence in validating and clearing this new drug therapy."
 Impression Delivery Corporation is a publicly traded holding company with businesses engaged in the food industry, biotechnology, and merchandising.
 -0- 2/22/93
 /CONTACT: Tom de Petra of de Petra & Associates, 612-338-7630 or 800-969-7630, for Impression Delivery Corporation/


CO: Impression Delivery Corporation ST: Minnesota IN: SU: TNM

AL -- MN023 -- 9121 02/22/93 18:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:354
Previous Article:BIOPLASTY, INC. ANNOUNCES RESIGNATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER
Next Article:UNITED STATES CELLULAR REPORTS SIGNIFICANT INCREASES IN 1992 REVENUES, CUSTOMERS AND CASH FLOW
Topics:


Related Articles
CEL-SCI CORPORATION NAMES TWO OUTSIDERS TO ITS BOARD OF DIRECTORS
ADVANCED BIOLOGICAL SYSTEMS' LICENSEE BEGINS TREATING AIDS PATIENTS IN THE CARIBBEAN; ROKA TREATMENT USES PLANT-BASED THERAPEUTICS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES PROPOSED ACQUISITION OF TARGETECH, INC.
IMPRESSION DELIVERY CORPORATION, INC. HALTS TRADING PENDING NEWS
ALPHA 1 BIOMEDICALS ENTERS INTO AN AGREEMENT TO SELL ITS 50% INTEREST IN AIDS TECHNOLOGY
ALZA TO PROMOTE BAYER'S MYCELEX(R) TROCHE
TARGETED GENETICS SELLS 3,500,000 SHARES OF COMMON STOCK
Sheffield Medical's Ion Pharmaceuticals Exercises License Option For Sickle Cell Anemia Therapy; Renews Sponsored Research Agreement
ALZA Acquires Mycelex(R) Troche in the U.S. From Bayer
VIRxSYS Granted Patent for Using HIV-based Lentiviral Vectors to Efficiently Deliver Therapeutic Genes into Hematopoietic Cells.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters